AI-generated analysis. Always verify with the original filing.
Nasus Pharma Ltd. announced a $15.0 million private placement of 2,695,425 ordinary shares and accompanying warrants to purchase 2,695,425 ordinary shares at $5.565 per share and warrant, priced at a premium to the last closing price. The warrants have an exercise price of $6.53 per share and expire on the earlier of two years from issuance or 30 trading days after the NS002 Pivotal Study top-line results announcement.